<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794780</url>
  </required_header>
  <id_info>
    <org_study_id>CQAB149BCN01</org_study_id>
    <nct_id>NCT01794780</nct_id>
  </id_info>
  <brief_title>A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator</brief_title>
  <official_title>A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This multi-center study is designed to describe natural history of disease, treatment and
      health care products in physician-diagnosed COPD patients who require adding daily
      maintenance therapy in real world.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline,3 months</time_frame>
    <description>Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline,12 months</time_frame>
    <description>Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD exacerbation</measure>
    <time_frame>Baseline,12 months</time_frame>
    <description>Number of COPD exacerbations evaluated over 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire MMRC</measure>
    <time_frame>Baseline,3,6,9,12 months</time_frame>
    <description>mMRC, uses a simple grading system to assess a patient's level of dyspnea. The mMRC scale is scored from 0 (less severe) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire CAT</measure>
    <time_frame>Baseline,3,6,9,12 months</time_frame>
    <description>CAT is designed to measure the impact of COPD on a person's life, and how this changes over time.The CAT score is based on eight domains with each domain scored from 0 (major improvement) to 5 (major deterioration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire TDI</measure>
    <time_frame>Baseline,3,6,9,12 months</time_frame>
    <description>Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">2253</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LABA based treatment: indacaterol</intervention_name>
    <description>LABA based treatment: indacaterol</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAMA based treatment: tiotropium</intervention_name>
    <description>LAMA based treatment: tiotropium</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LABA/ICS based treatment: salmeterol/fluticasone</intervention_name>
    <description>LABA/ICS based treatment: salmeterol/fluticasone</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LABA/ICS based treatment: budesonide/formoterol</intervention_name>
    <description>LABA/ICS based treatment: budesonide/formoterol</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>theophylline based treatment</intervention_name>
    <description>theophylline based treatment</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide informed consent

          -  Physician-diagnosis of COPD

          -  COPD patients requiring long-acting bronchodilator treatment

          -  Patients with spirometry available at baseline

        Exclusion Criteria:

          -  Patients who have a diagnosis of asthma.

          -  Patients who had been hospitalized for a COPD exacerbation in the 4 weeks prior to
             Visit 1.

          -  Current clinical diagnosis of other chronic respiratory illnesses

          -  Concurrent participation in a clinical trial or use of an investigational drug.

          -  Active malignancy or history of malignancy of any organ system

          -  Pregnant or nursing (lactating) women

          -  Women of child-bearing potential with no contraception Other protocol-defined
             inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2013</study_first_submitted>
  <study_first_submitted_qc>February 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <last_update_submitted>May 6, 2016</last_update_submitted>
  <last_update_submitted_qc>May 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
    <mesh_term>Theophylline</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 1, 2017</submitted>
    <returned>October 20, 2017</returned>
    <submitted>May 24, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

